Cargando…

N (6)-Methyladenine hinders RNA- and DNA-directed DNA synthesis: application in human rRNA methylation analysis of clinical specimens

N (6)-Methyladenine (m(6)A) is the most abundant internal modification on mammalian mRNA. Very recently, m(6)A has been reported as a potentially important ‘epigenetic’ mark in eukaryotes. Until now, site-specific detection of m(6)A is technically very challenging. Here, we first reveal that m(6)A s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shaoru, Wang, Jiaqi, Zhang, Xiaoe, Fu, Boshi, Song, Yanyan, Ma, Pei, Gu, Kai, Zhou, Xin, Zhang, Xiaolian, Tian, Tian, Zhou, Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Royal Society of Chemistry 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975930/
https://www.ncbi.nlm.nih.gov/pubmed/29910902
http://dx.doi.org/10.1039/c5sc02902c
Descripción
Sumario:N (6)-Methyladenine (m(6)A) is the most abundant internal modification on mammalian mRNA. Very recently, m(6)A has been reported as a potentially important ‘epigenetic’ mark in eukaryotes. Until now, site-specific detection of m(6)A is technically very challenging. Here, we first reveal that m(6)A significantly hinders DNA- and RNA-directed DNA synthesis. Systematic investigations of 5′-triphosphates of a variety of 5-substituted 2′-deoxyuridine analogs in primer extension have been performed. In the current study, a quantitative analysis of m(6)A in the RNA or DNA context has been achieved, using Bst DNA polymerase catalyzed primer extension. Molecular dynamics study predicted that m(6)A in template tends to enter into and be restrained in the MGR region of Bst DNA polymerase, reducing conformational flexibility of the DNA backbone. More importantly, a site-specific determination of m(6)A in human ribosomal RNA (rRNA) with high accuracy has been afforded. Through a cumulative analysis of methylation alterations, we first reveal that significantly cancer-related changes in human rRNA methylation were present in patients with hepatocellular carcinoma.